$INTI
Inhibitor Therapeutics, Inc.

2018 Q2 Form 10-Q Financial Statement

#000119312518145179 Filed on May 01, 2018

View on sec.gov

Income Statement

Concept 2018 Q2 2018 Q1 2017 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $360.0K $500.0K $1.990M
YoY Change 28.57% -74.87% 226.23%
% of Gross Profit
Research & Development $528.9K $674.0K $818.3K
YoY Change 19.99% -17.64% 40.48%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $884.4K $1.175M $2.813M
YoY Change 22.93% -58.24% 135.51%
Operating Profit -$884.4K -$1.175M -$2.813M
YoY Change 22.93% -58.24% 135.51%
Interest Expense $0.00 $0.00 $10.00K
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$880.0K -$1.170M -$2.800M
YoY Change 22.22% -58.21% 135.29%
Income Tax
% Of Pretax Income
Net Earnings -$881.9K -$1.171M -$2.801M
YoY Change 23.1% -58.21% 134.53%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share $0.00 $0.00 -$0.01
COMMON SHARES
Basic Shares Outstanding 369.7M shares 369.6M shares 353.4M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q2 2018 Q1 2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $800.0K $1.570M $2.340M
YoY Change -51.22% -32.91% 1850.0%
Cash & Equivalents $795.8K $1.573M $2.340M
Short-Term Investments
Other Short-Term Assets $290.0K $300.0K $300.0K
YoY Change 0.0% 0.0% 476.73%
Inventory
Prepaid Expenses $41.06K $51.36K $51.04K
Receivables
Other Receivables
Total Short-Term Assets $1.087M $1.875M $2.641M
YoY Change -43.82% -29.01% 1447.62%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $97.64K $105.0K $134.3K
YoY Change -23.08% -21.82% -46.3%
Total Long-Term Assets $97.64K $105.0K $134.3K
YoY Change -23.08% -21.82% -46.3%
TOTAL ASSETS
Total Short-Term Assets $1.087M $1.875M $2.641M
Total Long-Term Assets $97.64K $105.0K $134.3K
Total Assets $1.184M $1.980M $2.775M
YoY Change -42.54% -28.67% 559.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $326.2K $370.1K $339.7K
YoY Change 1.21% 8.95% -47.51%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $461.9K $441.2K $395.8K
YoY Change 36.02% 11.46% -46.76%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $461.9K $441.2K $395.8K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $461.9K $441.2K $395.8K
YoY Change 36.02% 11.46% -46.76%
SHAREHOLDERS EQUITY
Retained Earnings -$50.38M -$49.47M -$45.97M
YoY Change 7.91% 7.61% 23.03%
Common Stock $48.74M $51.01M $48.35M
YoY Change 0.69% 5.49% 30.53%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.638M -$822.4K $2.379M
YoY Change
Total Liabilities & Shareholders Equity $1.184M $1.980M $2.775M
YoY Change -42.54% -28.67% 559.73%

Cashflow Statement

Concept 2018 Q2 2018 Q1 2017 Q1
OPERATING ACTIVITIES
Net Income -$881.9K -$1.171M -$2.801M
YoY Change 23.1% -58.21% 134.53%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$790.0K -$1.132M -$870.0K
YoY Change 6.76% 30.08% 81.25%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 10.00K 2.361M -3.680M
YoY Change -80.0% -164.15%
NET CHANGE
Cash From Operating Activities -790.0K -1.132M -870.0K
Cash From Investing Activities
Cash From Financing Activities 10.00K 2.361M -3.680M
Net Change In Cash -780.0K 1.229M -4.550M
YoY Change 13.04% -127.01% 847.92%
FREE CASH FLOW
Cash From Operating Activities -$790.0K -$1.132M -$870.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
369674266 shares
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2339817
CY2018Q1 us-gaap Assets Current
AssetsCurrent
1874649
CY2018Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
50972277
CY2018Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
370090
CY2018Q1 us-gaap Assets
Assets
1979610
CY2018Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1573292
CY2018Q1 us-gaap Cash Uninsured Amount
CashUninsuredAmount
1300000
CY2018Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2018Q1 us-gaap Common Stock Value
CommonStockValue
36967
CY2018Q1 us-gaap Deposits Assets Current
DepositsAssetsCurrent
250000
CY2018Q1 us-gaap Dividends Payable Current
DividendsPayableCurrent
26630
CY2018Q1 us-gaap Liabilities
Liabilities
441162
CY2018Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1979610
CY2018Q1 us-gaap Liabilities Current
LiabilitiesCurrent
441162
CY2018Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
44442
CY2018Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
104961
CY2018Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2018Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
369674266 shares
CY2018Q1 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2018Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
369674266 shares
CY2018Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2253623 shares
CY2018Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2018Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2018Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
51357
CY2018Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-49471144
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
1538448
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6885422
CY2017Q4 us-gaap Assets Current
AssetsCurrent
655768
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
48403523
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
534956
CY2017Q4 us-gaap Assets
Assets
768052
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
344113
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
369599266 shares
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
369599266 shares
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
36960
CY2017Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
250000
CY2017Q4 us-gaap Liabilities
Liabilities
601489
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
768052
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
601489
CY2017Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
66533
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
112284
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2253623 shares
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
61655
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-48273920
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
166563
CY2017Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-4545605
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1994734
CY2017Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
87674
CY2017Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-17382
CY2017Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
11645
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-867878
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
2813072
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-3677727
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-2801427
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2813072
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
818338
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1828493
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
357644397 shares
CY2017Q1 hppi Net Settlement In Connection With Issuance Of Shares Associated With Restricted Stock Units
NetSettlementInConnectionWithIssuanceOfSharesAssociatedWithRestrictedStockUnits
3677727
CY2017Q1 hppi Fair Value Of Shares Withheld With Net Settlement Transaction
FairValueOfSharesWithheldWithNetSettlementTransaction
3677727
CY2017Q1 hppi Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-2801427
CY2018Q1 dei Amendment Flag
AmendmentFlag
false
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
208243
CY2018Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1229179
CY2018Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2018Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
26630
CY2018Q1 us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
26630
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.00
CY2018Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2018Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
CY2018Q1 dei Document Type
DocumentType
10-Q
CY2018Q1 dei Document Period End Date
DocumentPeriodEndDate
2018-03-31
CY2018Q1 dei Entity Registrant Name
EntityRegistrantName
HedgePath Pharmaceuticals, Inc.
CY2018Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001042418
CY2018Q1 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
500846
CY2018Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-186957
CY2018Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-17621
CY2018Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
4222
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-1131687
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
1174816
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
2360866
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-1170594
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1174816
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
673970
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
208243
CY2018Q1 dei Trading Symbol
TradingSymbol
HPPI
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
369615099 shares
CY2018Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> <i>Estimates</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> The preparation of condensed financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</p> </div>
CY2018Q1 hppi Stock Issued During Period Value New Issues To Related Party
StockIssuedDuringPeriodValueNewIssuesToRelatedParty
2360866
CY2018Q1 hppi Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-1197224
CY2018Q1 hppi Proceeds From The Sale Of Preferred Stock And Common Stock Warrants Related Party Net
ProceedsFromTheSaleOfPreferredStockAndCommonStockWarrantsRelatedPartyNet
2360866
CY2018Q1 hppi Accrued But Unpaid Dividends
AccruedButUnpaidDividends
26630

Files In Submission

Name View Source Status
0001193125-18-145179-index-headers.html Edgar Link pending
0001193125-18-145179-index.html Edgar Link pending
0001193125-18-145179.txt Edgar Link pending
0001193125-18-145179-xbrl.zip Edgar Link pending
d558032d10q.htm Edgar Link pending
d558032dex311.htm Edgar Link pending
d558032dex312.htm Edgar Link pending
d558032dex321.htm Edgar Link pending
d558032dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
hppi-20180331.xml Edgar Link completed
hppi-20180331.xsd Edgar Link pending
hppi-20180331_cal.xml Edgar Link unprocessable
hppi-20180331_def.xml Edgar Link unprocessable
hppi-20180331_lab.xml Edgar Link unprocessable
hppi-20180331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending